Nasdaq

Novartis to Acquire IFM Tre to Develop First-In-Class NLRP3 Antagonist Portfolio Targeting Innate Immune System

-- IFM to receive $310 million upfront, with up to $1.265 billion in milestones for a total of $1.575 billion BOSTON, April 1, 2019 /PRNewswire/ -- IFM Therapeutics (IFM), a privately held ...
Nasdaq

Novartis Acquires IFM Due to Develop First-In-Class STING Antagonist Program Targeting Innate Immune System

Milestone marks the third major acquisition for an IFM Therapeutics subsidiary in the past seven years The acquisition provides Novartis with full rights to IFM Due's portfolio of STING antagonists, ...
Forbes

Five Reasons Why Facilities Management Should Be A Top Priority In 2023

Rob Almond is the CEO of NEST, the pioneer of Integrated Facilities Management (IFM) in North America since 1994. Follow NEST on LinkedIn. Why is facilities management critical? If you ask five ...
WGHP

Novartis Acquires IFM Due to Develop First-In-Class STING Antagonist Program Targeting Innate Immune System

BOSTON, March 13, 2024 /PRNewswire/ -- IFM Therapeutics (IFM), a privately held biopharmaceutical company focused on developing therapies that modulate novel targets in the innate immune system, ...